Re: 3/13/01 - [IVEH] Ives Health threatens to sue "certain members of the press"
=====
Ives Health Company Retains Strategic Communications for Investor Relations
Company Will Focus on Shareholder Value
CLAREMORE, Okla., Jan 25, 2001 (BW HealthWire) -- Ives Health Company (OTCBB: IVEH chart, msgs) announced today that it has retained the services of Strategic Communications, a leading investor and media relations firm.
Keith Ives, Founder of Ives Health Company said: "After thoroughly investigating many investor and public relations options, we have decided that Strategic Communications has the best track record for effectively communicating with the public. Our products offer the best Naturalpath Health Solutions on the market and we will do the public and the media a service by telling them."
A spokesperson for Strategic Communications said: "We are very particular in the companies that we choose to represent. Because we expose a company's story through traditional methods, without hype, it is important that the story has real value. We believe that Ives Health Company and their products have tremendous upside potential and will work hard to present the company to every possible media outlet, broker, analyst, and money manager."
About Ives Health Company
Ives Health Company is committed to improving consumers' "Total Health" through their high-quality natural remedies and homeopathic medicines. Ives product formulations use 98.3% pure natural ingredients and deliver an astounding 90% of the active ingredients into the bloodstream. The Company's products compete in the $99.2 billion diet and nutritional product arena under the following branded names: Pharmacy Health and Diet Program(TM), T-Factor(TM) Immune Enhancement System, Vegi Bears(TM) (a nutritional snack) and other natural remedies for Aches & Pains, Acne (a non-topical oral treatment), Allergy, Antacid, Arthritis, Cough & Sore Throat, Energy, Headache, Sinus, PMS relief, Prostate relief, Cholesterol control among others. Please visit iveshealth.com to purchase or to learn more about the Ives family of homeopathic medicines, weight management and natural remedy products.
This news release includes "forward-looking statements" that include risk and uncertainties. The forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including without limitation the Company's ability to produce and market products and/or services and other risks detailed from time to time in their Company's reports filed with the Securities Exchange Commission. Please consult with your physician prior to starting a weight loss program.
Contact:
For Ives Health Company:
Strategic Communications
Wayne Schumacher, 775/828-6576
siliconinvestor.com
=====
Ives Health to Post Summary of the Landmark Java Project That Proves ``T-Factor'' Increases T-Cell (CD-4) Cell Count in HIV/AIDS Patients
CLAREMORE, Okla., Feb 19, 2001 (BW HealthWire) -- Ives Health Company (OTCBB: IVEH chart, msgs):
Public Unveiling of the Java Project Study
Ives Health Company (OTCBB: IVEH chart, msgs) announced today that in order to facilitate the public's unbelievable response to T-Factor(R) and the Java Project, the Company is making a brief summary of the Project, that will include patient profiles, available at iveshealth.com.
The results of this groundbreaking study are now gaining worldwide attention from both the investment and healthcare communities.
Keith Ives, President and Founder of Ives Health Company, stated: "The sheer amount of excitement surrounding this product has been daunting. When we found the product three years ago, T-Factor(R) was an unsightly paste that had to be administered through a stomach tube. Thanks to years of dedicated research, we have solved the problems of putting the formula in a pill that is easily swallowed, and preserving that formula until it reaches the consumer. This has required both hard work and vision on the part of our team, our investors, and our clients. We could not be more enthusiastic about helping to improve the lives of hundreds of millions of people who are infected with HIV."
T-Factor(R) was released to the public on February 13, 2001, on Ives Health Company's website at iveshealth.com. Mr. Ives continued: "Because the product has almost no side effects, we are trying to get the word out through HIV and AIDS support groups around the country. We are also attempting to have the product tested and notarized by a celebrity who is battling HIV. HIV is a terrible virus and the enthusiasm that the investment community is showing over T-Factor will help us get the word out to millions of people who desperately need our help."
About the Java Project and T-Factor(R)
The Java Project was a landmark AIDS study carried out by Dr. Slayton-Bedeen, an Immunologist and T-Factor(R) Founder, along with the World Health Organization in Jakarta and Bangkok. The project found that new hormonal inhibitors of the Human Immunodeficiency Virus (HIV), like T-Factor(R), might initiate profound and sustained suppression of HIV replication. The T-Factor(R) formula was administered to 186 HIV-Positive patients of Asian descent with elevated HIV RNA and decreased CD-4 counts, over a period of 24 weeks. The results were dramatic, with over 80% of patients experiencing documented decreases in HIV RNA and enhanced CD-4 counts after 24 weeks.
The T-Factor(R) formula, acquired by Ives Health Company in 1998, is all-natural, has virtually no side effects, and is readily available over the Internet at iveshealth.com. T-Factor(R) costs less than $3.00 per day versus $80.00 per day for current HIV drug therapies. New studies are on-going in the United States and recently began in Europe. Findings will be released as the data is reported and validated. T-Factor(R) is not a cure for HIV, but is intended to extend the lives of those inflicted with the virus.
About Ives Health Company
Ives Health Company is committed to improving consumers "Total Health" through their high-quality natural remedies and homeopathic medicines. Ives product formulations use 98.3% pure natural ingredients and deliver an astounding 90% of the active ingredients into the bloodstream. The Company's products compete in the $99.2 billion diet and nutritional product arena under the following branded names: Pharmacy Health and Diet Program(R), T-Factor(R) Immune Enhancement System, Vegi Bears(TM) (a nutritional snack) and other natural remedies for Aches & Pains, Acne (a non-topical oral treatment), Allergy, Antacid, Arthritis, Cough & Sore Throat, Energy, Headache, Sinus, PMS relief, Prostate relief, and Cholesterol control, among others. Please visit iveshealth.com to purchase or to learn more about the Ives family of homeopathic medicines, weight management and natural remedy products.
This news release includes "forward-looking statements" that include risk and uncertainties. The forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including without limitation the Company's ability to produce and market products and/or services and other risks detailed from time to time in their Company's reports filed with the Securities Exchange Commission. Please consult with your physician prior to starting a weight loss program.
Contact:
For Ives Health:
Strategic Communications
Investor Relations, 775/828-6576
or
www.iveshealth.com
siliconinvestor.com
=====
UPDATE 1-SEC suspends trade in Ives Health through March 16
(Adds details)
WASHINGTON, March 5 (Reuters) - Federal securities regulators on Monday suspended trading in Ives Health Co. Inc. (IVEH) through March 16, questioning the accuracy of claims the firm has made about an HIV treatment.
The Securities and Exchange Commission said in a statement that it issued the suspension because of "questions regarding the accuracy of public statements by Ives Health to investors concerning, among other things, a product being marketed by Ives Health for treatment of human immunodeficiency virus."
Ives Health, based in Claremore, Okla., closed at 25 cents on Friday on the OTC bulletin board.
Ives was not immediately available for comment.
The company has a line of homeopathic medicines and other natural remedies to treat acne, coughs, headaches and sore throat, it said in a recent statement.
It is also owns T-Factor, "an all-natural remedy that has been proven to increase T-Cell counts in HIV patients," according to a Feb. 27 statement.
The company's Web site is iveshealth.com.
siliconinvestor.com
=====
Convicted Stock Swindler Helped Promote Shares of Ives Health
Chicago, March 12 (Bloomberg) -- When Ives Health Co. stock was surging earlier this year, an ex-Chicago stockbroker named Wayne Schumacher had a big hand in it.
The company, which uses the Internet to sell what its says is a ``breakthrough'' drug for HIV, hired Schumacher to promote its stock in January. He was hired a week after the Federal Bureau of Prisons said Schumacher completed a one-year sentence for securities fraud.
Since then, Ives' claims about the medicine's value have been questioned by the Securities and Exchange Commission, which suspended trading in the company's stock last Monday.
Keith Ives, president of Ives Health, said he didn't know Schumacher was a convicted felon when he hired him and an associate, Robert Pierce, of Reno, Nevada, to do public relations and Web site design.
Ives, which gave 3 million shares of company stock to Pierce, isn't concerned about Schumacher's background. ``Our company is fine with him,'' Ives said Friday.
Schumacher didn't return messages left at the Chicago telephone number he shares with Pierce.
The SEC, in stopping trading in Ives Health on the OTC Bulletin Board for 10 days, cited concerns about the truth of the Claremore, Oklahoma-based vitamin company's marketing claims for T- Factor, the drug it claims can halt the progression of HIV.
The day of the suspension, Bloomberg News reported the research behind T-Factor was conducted by a former Ives executive, Robert Slayton-Bedeen, who was fired after the company discovered he used multiple aliases. Bloomberg also reported Ives' claim that the World Health Organization tested the drug and found it effective was disavowed by the Geneva, Switzerland-based group.
Secret Payoffs
Schumacher, 35, pleaded guilty in January, 2000, in federal court in West Palm Beach, Fla., to conspiring to commit securities fraud, mail fraud and wire fraud. His indictment accused him of taking payoffs from a stock promoter to sell certain stocks to his clients. Released from prison on Jan. 17, he quickly went to work for Ives Health and began distributing press releases, including one on Feb. 15 that announced T-Factor was now available for sale on the Internet.
``Ives Health's T-Factor, an all-natural therapy, increases T- Cell Count in HIV positive patients,'' was the headline.
Ives shares soared from 8 cents to a high of 74 cents the next day. The stock, which traded 19.1 million shares in February, was last quoted at 25 cents.
And what's Schumacher, who hung his hat at eight different firms over his seven-year career as a stockbroker, doing now? Still working for Ives Health, Ives says.
Assistant U.S. Attorney Rolando Garcia, who prosecuted Schumacher in Florida, says he is concerned about the former broker's activities because promoting a penny stock may violate the terms of his probation, which forbid him from working in securities-related businesses.
''We're certainly going to be checking with the probation office concerning his present conduct,'' Garcia said.
Mar/12/2001 9:39 ET
For more stories from Bloomberg News, click here.
(C) Copyright 2001 Bloomberg L.P.
=====
Freespace Media Clarifies Position With Ives Health
RENO, NV, Mar 13, 2001 (INTERNET WIRE via COMTEX) -- In an official statement made by the Company, Freespace Media attempted to clarify its working relationship with Ives Health (OTCBB: IVEH chart, msgs).
"It upsets us greatly that we feel the need to do this, but it seems that there have been so many misconceptions and inventions propagated by certain members of the public and the media lately that we are forced to publish a statement", said a spokesperson for the Freespace Media.
Freespace Media was hired by Ives Health Company on January 2, 2001 to develop a new corporate identity, new media kit, and an E-Commerce website for the Ives Health Company. The total cost to construct and support these efforts was estimated at $150,000. Because Ives Health Company was unable to pay for the services in cash and because Ives stated that distributing product would be the only way to make money, it was agreed that a Managing Member of Freespace Media would accept free-trading stock for the value of the contract. Ives protected its investors by having Freespace write a note against the stock and the shares were distributed to Freespace in stages as necessary milestones were reached. Freespace Media is not an investor or public relations firm for Ives Health Company or any of its clients.
In response to recent questions regarding the name of a Freespace employee appearing as the Investor Relations contact for a press release issued on January 25th, 2001, the spokesperson said, "The confusion over Wayne Schumacher's involvement with Ives Health Company has drawn attention from the media recently. This confusion was caused by a miscommunication within Ives Health Company. The way it has been explained to us by Ives is that they submitted the press release to a national newswire with their Investor Relations name and phone number. The newswire apparently called Ives and asked for a contact name for the press release. Knowing only that the press release was about a new partner, the individual at Ives incorrectly assumed that Freespace Media was the subject of the release and Wayne Schumacher, the salesperson on the account, was the contact. It was an unfortunate yet forgivable error on Ives part and because of the clarity of our dealings with Ives we never assumed that much would come of it."
The spokesperson continued, "Despite accounts by the media, Mr. Schumacher has been employed by Freespace Media since November 21, 2000 and is not directly employed by Ives Health Company in any capacity to the best of our knowledge. The management of Freespace Media had no previous relationship with Mr. Schumacher but had heard of his story and wanted to help him enter a new career. Freespace Media hired him for our Chicago office based on his sales experience and his job is to sell website development services to clients and maintain those client relationships. Because we do not have enough information at this time, Mr. Schumacher has been suspended pending an internal investigation into whether or not he was involved in any stock promotion. At this time, the Company feels that allegations leveled at Mr. Schumacher by certain members of the press are wholly unfounded and we will seek damages from the offending individuals should we find that their malicious intent outweighed their fiduciary responsibility to the public."
Freespace Media does not plan to make further information available to the public and asks that all questions regarding Ives Health be directed to Ives' representatives. Freespace Media also has no further plans to announce publicly its intent to file lawsuits against any media organization or its representatives should such action be taken.
This news release includes "forward-looking statements" that include risk and uncertainties. The forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to a variety of factors, including without limitation the Company's ability to produce and market products and/or services and other risks detailed from time to time in their Company's reports filed with the Securities Exchange Commission. Please consult with your physician prior to starting a weight loss program.
CONTACT: Robert Pierce
Freespace Media
866-422-6918
Copyright 2001 Internet Wire, All rights reserved.
siliconinvestor.com
===== |
